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Abstract: Hyaluronan (HA) is among the most important bioactive polymers in mammals, playing
a key role in a number of biological functions. In the last decades, it has been increasingly studied
as a biomaterial for drug delivery systems, thanks to its physico-chemical features and ability to
target and enter certain cells. The most important receptor of HA is ‘Cluster of Differentiation 44’
(CD44), a cell surface glycoprotein over-expressed by a number of cancers and heavily involved in
HA endocytosis. Moreover, CD44 is highly expressed by keratinocytes, activated macrophages and
fibroblasts, all of which can act as ‘reservoirs’ for intracellular pathogens. Interestingly, both CD44 and
HA appear to play a key role for the invasion and persistence of such microorganisms within the cells.
As such, HA is increasingly recognised as a potential target for nano-carriers development, to pursuit
and target intracellular pathogens, acting as a ‘Trojan Horse’. This review describes the biological
relationship between HA, CD44 and the entry and survival of a number of pathogens within the cells
and the subsequent development of HA-based nano-carriers for enhancing the intracellular activity
of antimicrobials.
Keywords: hyaluronan; intracellular infections; CD44; nano-carriers; antimicrobial delivery
1. Introduction
Intracellular pathogens are considered to be among the major bacterial public health threats [1].
The outcome of intracellular infections is largely due to the ability of pathogens to utilise specific
cell receptors [2] and host components [3] for invading and subverting cellular activities. Evidences
suggest a number of microorganisms can utilise hyaluronan (HA) and/or Cluster of Differentiation 44
(CD44) [4–6], an important receptor for HA [7–9], to promote attachment, invasion and replication
within the cells. This ability has been recognised to be a potential factor in persistent infections and
treatment failure.
Despite the ability of certain antibiotics to cross cell membrane, their intracellular efficacy can
be poor due to: (I) intracellular concentrations below the minimum inhibitory value; (II) intracellular
environment (e.g., acidic pH) that may affect the antibiotic activity; (III) antibiotic accumulation in
subcellular compartments that are different from those in which pathogens reside.
In 1934, Karl Meyer and John Palmer isolated an unknown chemical substance from the vitreous
body of bovine eyes, which contained two sugar molecules [10]. As one of these sugar molecules was
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an uronic acid, the name “hyaluronic acid” (HA) was coined by joining three words: hyaloid (vitreous)
and uronic acid. Further work by Karl Meyer and his associates led to the resolution of the chemical
structure of HA by the 1950s [11]. HA is a linear and non-sulfated glycosaminoglycan (Figure 1A),
a poly-anionic polysaccharide composed of alternating D-glucuronic acid and N-acetyl-D-glucosamine
monomeric units linked together through β-1,4 and β-1,3 glycosidic bonds. In early 1980s, Endre Balazs
was successful in isolating a purified high molecular weight HA, which was used to produce plastic
intraocular lenses for implantation [12]. In 1986, the term “hyaluronan” was introduced, to encompass
the various forms the HAmacromolecules could take: the acid form, hyaluronic acid, and its salts, such
as sodium hyaluronate, which forms at physiological pH [13]. The injectable form of HA (‘Hyalgan®’)
was approved in 1997, by the FDA for the treatment of pain associated with knee osteoarthritis by
viscosupplementation [14] and, more recently, thanks to its biocompatibility, biodegradability [15] and
its ability to provide high osmotic pressure and hydration, HA has found a market as a biomaterial in
the cosmetic industry [14,16] and ophthalmology [17].
An important in vitro receptor of HA is CD44 [18] (Figure 1B); after the binding with HA, CD44
facilitates: (I) HA endocytosis [19] (Figure 1C) and (II) signalling events that generate a number
of cell specific responses [18]. Cells which are known to highly express CD44 and internalise HA
are keratinocytes [20], activated macrophages [21], fibroblasts [22], chondrocytes [23] and certain
cancer cells [18,24]. The first three cell lines can act as ‘reservoirs’ of intracellular pathogens and,
more interestingly, a number of works have shown these pathogens can utilise CD44 and/or HA for
invading and surviving within such cells. Consequently, the incorporation/linkage of antimicrobials
into HA-based nano-carriers represents a novel paradigm in the delivery of therapeutics against
intracellular pathogens, as HA may enhance the sub-cellular targeting in addition to the efficacy of
such antimicrobials by enabling the system to act as a ‘Trojan Horse’.
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Figure 1. (A) Chemical structure of the HA repetitive unit. (B) Model structure of the standard CD44
receptor. (C) Schematic overview of HA endocytosis and degradation within the cells. ((C) reproduced
with permission from © 2012 Racine R, Mummert ME. Published in Molecular Regulation of Endocytosis,
IntechOpen, 2012, under CC BY 3.0 license. Available from: http://dx.doi.org/10.5772/45976 [19]).
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2. Biodistribution and Roles of HA
HA is a bioactive polysaccharide that naturally occurs in all living organisms [25], it is mostly
found in the extracellular and pericellular matrices [26] such as the connective tissues, synovial fluid
of joints and vitreous humour of the eye, however, intracellular locations such as the cytoplasm
and vesicles, have also been documented [26]. In mammals, HA is synthesised by at least three
synthases (HAS1, HAS2 and HAS3) [27] with expression of HAS genes appearing to be both tissue-
and site-specific [28]. These enzymes (which are glycosyltransferases) differ from each other in their
catalytic activities (HAS3 > HAS2 > HAS1) as well as in the size of their final products [29].
Degradation of HA typically occurs through a step-wise process [30] and its turnover can occur
locally (in the cellular micro-environment) or at the tissue level. The local degradation includes: (I) HA
binding, predominantly via CD44 [18] or via receptor for HA-mediated motility (RHAMM) [31,32];
(II) internalisation; (III) degradation within the cells by a series of coordinated enzymatic reactions
in which HA fragments of decreasing size are progressively generated [33]. For the turnover at the
tissue level, HA is released from tissue matrices, drained into vascular and lymphatic systems and
then predominantly removed by liver and kidney [34]. The receptors involved in this pathway are HA
receptors for endocytosis (HARE) [35] or lymphatic vessels endothelial HA receptors (LYVE-1) [36].
The enzymes required for HA synthesis and degradation are also involved in producing specific
HA molecular weights, which in turn are related to specific functions of the HA fragments [37].
Furthermore, both location and HA concentration are also important variables in relation to the
biological role that HA will take within the body [38]. High molecular weight HA (>1000–5000
repeating units) are typically extracellular, space-filling and have several structural functions which
include lubrication of movable parts of the body, such as joints and muscles [39] and the maintenance
of the viscoelasticity of connective tissues [39,40]. Moreover, high molecular weight HA controls the
supramolecular assembly of proteoglycans in the extracellular matrix [38] and it is involved in the
suppression of the angiogenesis [41] and immune-system [42]. In contrast, the small HA fragments
appear to act as endogenous ‘danger signals’ [43], playing an active role in inflammation [44,45],
immune-stimulation [46], cell detachment [47], migration [48] and tumour development [49].
Despite current data, there is a degree of uncertainty in HA biology; areas which require further
exploration, include (I) the mechanism by which enzymes of synthesis and degradation of HA are
able to cooperate for providing a proper HA size, (II) the binding of HA to CD44 and the subsequent
internalisation within the cells; (III) the explicit role HA plays during the inflammation: evidences
suggest in the alveolar tracts, released fragments of HA play a pivotal role in the host defenses,
stimulating the innate immune responses, by activating TLR2 and TLR4 receptors promoting lung
inflammation [50] and HA role in the resolution of inflammation, [51] and (IV) the role HA plays
during the infection processes. The latter is one of the main focus of this review.
3. CD44-Mediated Uptake of HA in Host Cells
CD44 is a widely expressed family of class I transmembrane glycoproteins present on the surface
of most mammalian cells [18,52]. CD44 is formed by an amino-terminal domain, which is known as
the ‘link domain’ that enables the receptor to bind to HA as well as other glycosaminoglycans [53]
(Figure 1B). The amino-terminal domain is separated from the plasma membrane by a short stem
structure, which is followed by the transmembrane region and the cytoplasmic-tail [54,55]. After the
binding with HA, CD44 works especially for two purposes: (I) to allow the HA endocytosis; (II) to
trigger signalling events that induce a number of cell specific responses. In 2003, R. Stern proposed a
general mechanism for the endocytosis of high molecular weight HA (hMWHA) and its catabolism
within the cells [33] (Figure 1C). He proposed that hMWHA (Mw ≥ 1 × 10
6) is first degraded by the
combined action of HA receptors and hyaluronidase2 (HAase2) into intermediate-sized fragments
(Mw ≈ 1 × 10
4) and then it is taken up by the cells. These fragments are then delivered to endosomal
and lysosomal vesicles where a further catabolism could occur by HAase1, coordinated with the activity
of two specific lysosomal enzymes; finally, HA fragments are exocytosed [33].
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HA binding and uptake through CD44 appear to be two separate events that often do not take
place simultaneously. Evidences suggests that the HA uptake requires the acylation of the CD44
cytoplasmic tail [56] which can be a cell type specific event. Specifically, it was reported CD44 is
associated with cholesterol-rich lipid rafts [57] and this association is dependent on the palmitoylation
of both Cys286 and Cys295, which are in the highly conserved transmembrane domain and in the
proximal cytoplasmic domain of CD44, respectively [58]. The prevention of CD44 localisation within
lipid rafts blocks HA internalisation as well as the turnover/cycling of the receptor itself, but does not
interfere with the ability of the receptor to bind to HA [56]. This evidence may explain why HA is not
internalised in all CD44 expressing cell types.
Overall, cells that highly express CD44 and take up HA, leaving aside cancer cells [18,24],
are keratinocytes [20], activated macrophages [21], fibroblasts [22] and chondrocytes [23]. In 2001,
Tammi and colleagues showed keratinocytes express high level of CD44 and are able to internalise
exogenous HA; however, HA and especially HA oligosaccharides can also enter keratinocytes via
non-receptor mediated pathway [20]. Intracellularly, HA can be found in small vesicles with a diameter
of ~100 nm, which are close to the plasma membrane and in larger perinuclear structures (>1 µm).
Interestingly, a similar HA intracellular profile was found in liver endothelial cells [59]. These cells
showed a greater ability to internalise HA, particularly into vacuoles with a diameter ranging from 0.3
to 1.2 µm, with the majority located close to the perinuclear region. The HA binding and internalisation
profile has also studied in healthy human skin, normal scar and hypertrophic scar fibroblastic cell
lines. These cells lines showed similar binding as well as internalisation curves of HA for all cells
tested [24]. Moreover, normal scar fibroblasts showed greater ability to generate HA-derived partial
degradation products.
Alveolar macrophages reside in the respiratory tract and alveolar space, where they are
responsible for the uptake and clearance of pathogens as well as debris. These cells bind and take up
HA in a CD44-dependent manner [60]; once internalised HA was found in the cytoplasm. Evidences
also suggest that these cell types are the only immune cells that show to bind high levels of HA under
homeostatic, non-infectious or non-inflammatory conditions, in both rodents and humans [58].
4. Role of CD44 and HA in the Uptake and Proliferation of Intracellular Pathogens
Keratinocytes, macrophages and fibroblasts can all act as ‘reservoirs’ for intracellular pathogens.
Interestingly both HA and CD44, are utilised by a number of microorganisms to facilitate their
invasion of such cells and persistence within the cellular micro-environment (Table 1). For example,
Streptococcus pyogenes has been shown to be able to attach to epithelial cells through its HA-rich
polysaccharide capsules, which mediates attachment to CD44 receptors on pharyngeal and epidermal
keratinocytes [4,61] facilitating colonisation and infection in the throat and skin [61]. HA also appears
to play a key role in the adherence of Mycobacterium tuberculosis to human lung epithelial cells (A549) [5].
Evidence suggest that M. tuberculosis utilises extracellular DNA-binding proteins to attach host cells
through HA, indicating that HA represent the major binding site of M. tuberculosis in A549 cells; whilst
CD44 appears to be involved in the binding and subsequent cellular internalisation of M. tuberculosis in
murine primary macrophages [7]. CD44 is also implicated in the cellular uptake of Staphylococcus aureus
in human neutrophils [8], possibly influencing the pathogen phagocytosis through its structural and
functional linkage to the cytoskeletal microfilaments. A similar outcome was obtained for the cell
internalisation of Shigella spp. in epithelial cells [62] where it appears that CD44 associates with Shigella
spp. through IpaB, a protein which is secreted by the pathogen upon cell contact [62]. This IpaB-CD44
interaction led to the transduction of signals which participate in the cytoskeletal rearrangements and
the subsequent internalisation of the pathogen within the cells. CD44 has also been shown to facilitate
the intracellular growth of Listeria spp. in murine primary macrophages and fibroblasts. However,
this may not be an ubiquitous effect; as comparisons, in Salmonella enterica serovar Typhimorium,
CD44 did not play a role in their intracellular growth [9].
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Once internalised, the ability of the microorganism to proliferate intracellularly is another
advantage to survival. HA also seems play a role in this stage of infection. Evidence suggests that HA
is important for the growth of the parasite Leishmania in primary and RAW 264.7 macrophages [6].
A study by Naderer et al. [6] indicates that HA is taken up by infected macrophages and is transported
to the phagolysosome where Leishmania replicates; once internalised, HA provides Leishmania with
essential nutrients for growth and virulence. With the aim to investigate this aspect the strategy
adopted by the Nader group was generate N-acetylglucosamine (GlcNAc) acetyltransferase (GNAT)
deficient Leishmania (∆gnat). This mutant was unable to grow or survive even when macrophages
were cultivated in the presence of exogenous GlcNAc, suggesting intracellular HA provides Leishmania
with essential carbon sources [6].
Other microorganisms have also been shown to utilise HA as a nutrient source for intracellular
groth; for example strains of M. tuberculosis and Mycobacterium bovis bacillus Calmette-Guerin (BCG,
an attenuated strain of M. bovis and a live vaccine against tuberculosis) have been shown to be able to
utilise HA as a carbon source for proliferation [63]. In order to investigate this, 3H-labeled HA was
added to an infection cell culture model where it was found to be incorporated into the live BCG,
demonstrating HA uptake by the pathogen. Further work using L-Ascorbic acid 6-hexadecanoate
(Vcpal), which is an inhibitor of HAase, suppressed the enhancing effect of HA on the growth of
Mycobacteriae, suggesting: (I) short HA chains are preferred as a carbon source; (II) Mycobacteriae utilise
the exogenous HA [63].
Further experiments by theMatusmoto group also demonstrated that both BCG andM. tuberculosis
grew when co-cultured with HA-synthase1 (HAS1) and HAS3 (which synthesise HA with a broad
range of molecular weights, ranging from 2 × 105 to 2 × 106) but not HAS2 (which synthesises
HA with molecular weights higher than 2 × 106), confirming shorter HA chains are preferential
for growth. Specifically, HAS1 appeared to be the major HA synthase in Mycobacteriae-infected
mouse lungs [63] Treatment with hyaluronidase inhibitors (such as Vcpal, apigenin or quercetin [64])
could be an interesting approach to begin to give both an indication about which size range
is preferential for growth and information about the intracellular or extracellular use of HA by
the pathogen. However, to confirm the use of intracellular HA, radiolabelled HA should be also
employed. Another interesting approach could be the use of HA synthesis inhibitors (such as
4-methylumbelliferone, 4-MU) [65]. Among the inhibition mechanisms, 4-MU appears to work as a
competitive substrate for UDP-glucuronosyltransferase (UGT), which is an enzyme involved in HA
synthesis [66]. The application of such treatment should confirm the need of certain pathogens to use
HA for growth and virulence. Interestingly, the utilisation of HAase inhibitors, such as Vcpal [67],
apigenin or quercetin [64] have been shown to suppress the growth of Mycobacteriae in mouse lungs,
evidencing that HAase or a potential transporter of short size HA fragments could be potential targets
for therapies against such pathogens.
Table 1. CD44 and HA involvement in the host cell infections.
Pathogen Cell Line CD44 Role HA Role
S. pyogenes [4] Human keratinocytes
CD44 represents the main receptor for
cell attachment.
HA-based capsules are
synthesised for promoting the
cell invasion.
S. pyogenes [61]
Murine epithelial
keratinocytes
CD44 is found to be widely expressed in the site of
infection, acting as a major cellular receptor for the
cellular entry.
HA-based capsules are
synthesised for promoting the
cell invasion.
M. tuberculosis [5]
Human lung
epithelial cells
Employment of extracellular
DNA-binding proteins to attach
host cells through HA.
M. tuberculosis [7] Murine macrophages
CD44 involvement in the binding and subsequent
cellular internalisation.
S. aureus [8] Human neutrophils
CD44 influences the pathogen phagocytosis
through its structural and functional linkage to the
cytoskeletal microfilaments.
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Table 1. Cont.
Pathogen Cell Line CD44 Role HA Role
Shigella spp. [62]
Human
epithelial cells
The IpaB-CD44 interaction leads to the
transduction of signals that participate in the
cytoskeletal rearrangements and the subsequent
internalisation of the pathogen within the cells.
Listeria spp. [9]
Murine macrophages
and fibroblasts
CD44 facilitates the intracellular growth of the
pathogen intracellularly.
M. tuberculosis [63]
Human lung
epithelial cells
Short HA chains are utilised as a
carbon source for proliferation.
M. bovis bacillus
Calmette-Guerin [63]
Human lung
epithelial cells
Short HA chains are utilised as a
carbon source for proliferation.
Leishmania [6] Murine macrophages
HA acts as endogenous essential
nutrient for the growth
and virulence.
Taking together these data, it is reasonable to assume HAmay be a suitable biomaterial for building
nano-carriers to target intracellular pathogens, acting as ‘Trojan Horse’, as: (I) a number of host cells
(e.g., keratinocytes and macrophages) highly express CD44 and internalise HA; (II) HA can enter cells
throughCD44 receptor that is also used by such pathogens for the cell invasion; (III) like other nanoparticles,
HA nano-carriers can be engineered in order to target sub-cellular compartments (e.g., lysosome or
cytoplasm) where the microorganism grows and replicates; IV) HA nano-carriers may be cleaved by
HAase that are produced by several pathogens, such as Staphylococcus spp. and Streptococcus spp. [68],
facilitating the release of the drug in situ. Moreover, the depolymerisation/degradation of HA can also
occur in the presence of host enzymes, free radicals [15], and at low pH values, leading to the drug release
intracellularly, thus guaranteeing the efficacy of the targeted therapy also against microorganisms that
typically do not produce HAase.
5. HA-Based Nano-Carriers in Drug Delivery
In recent years, HA has received enormous attention as a biomaterial for building nano-carriers,
thanks to its biocompatibility, low-toxicity, biodegradability, hydrophilicity, ability to protect the entrapped
drug and to enhance the solubility of hydrophobic molecules. Furthermore, HA chains can be easily
functionalised, in order to develop materials suitable for drug delivery. Chemical modifications of HA
have been extensively reviewed [69,70] and target three functional groups: the carboxylic acid group,
the primary and secondary hydroxyl groups, and the N-acetyl group (following deamidation). In the
last decades, several kinds of HA-based nano-carriers have been developed, including self-assembling
nanohydrogels (NHs) [71–73], covalently [74,75] or physically cross-linked nanoparticles, HA-coated
liposomes [76,77] or inorganic nanoparticles [78,79] and bio-conjugates [80,81], and employed for a wide
range of applications [82,83]. A number of stimuli-responsive HA nano-carriers have been also developed
for the targeted and responsive delivery of therapeutics [84,85].
For example, HA-based nanoparticles are produced by using a number of strategies and are
classified by the type of cross-linking from which they are formed: the most common nanoparticles are
made by hydrophobic associations [71], chemical cross-linking [74] or electrostatic interactions [86].
HA nanoparticles made up of hydrophobic associations are usually obtained through the partial
hydrophobisation of HA; both hydrophobic molecules and/or hydrophobic long chains can be grafted
to HA, to obtain self-assembled nano-structures with internal hydrophobic domains, in aqueous
environment. Specifically, 5β-cholanic acid [73], cholesterol [71], 2′3′4′5′-tetrabutyrilriboflavin [72],
PLGA [87] and PEG-PCL [88] have been successfully linked to HA, allowing the formation of HA
nanoparticles, usually named nanohydrogels (NHs). Self-assembling HA NHs can be used to deliver a
wide range of therapeutic molecules or polypeptides [71,89]. However, the HA poly-anionic nature
represents a limitation in encapsulating negatively charged macromolecules such as siRNA and
DNA. To overcome this drawback, HA chains have been modified with mono-functional fatty amines
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(with different alkyl chain lengths) or cationic polyamines, such as polyethyleneimine, or poly(L-lysine),
in order to achieve self-assembled HA NHs, capable to physically encapsulate and deliver genetic
material [90].
Chemically cross-linked nanoparticles are usually more stable than the physically cross-linked
analogues. However, themethods used for forming cross-linked nanoparticles, such as themicro-emulsion
method [91], generally require high energy sources and drastic conditions (such as high speed mechanical
stirring or the use of organic solvents and surfactants), which, for example, represent a limitation for the
entrapment of sensitive molecules. Moreover, the permanent cross-linkages may inhibit drug release at
the target site, resulting in a reduced therapeutic efficacy. Therefore, several degradable linkages including
di-sulfide [92] and other pH-sensitive derivatives [93], have been used to obtain chemically cross-linked
stimuli-responsive nanoparticles. For example, HA-boronate derivative has been synthesised with the
aim to develop pH-responsive and chemically cross-linked nanoparticles [85], by spontaneously forming
boronate esters with polycatechols, by very mild conditions. The same strategy was also applied for the
development of pH-responsive HA bio-conjugates with a number of diol/catechol-based therapeutics [81].
The ionotropic gelation process represents another useful technique to prepare physically
cross-linked HA nano-carriers. An example is represented by HA/chitosan nanoparticles [86]:
the strong ionic interactions between the positively charged chitosan amino groups and the negatively
charged HA carboxylic groups allow the nanoparticle network’s formation.
Among the advantages that HA-based nano-carriers offer, the binding of HA to CD44, is one
of the most relevant; this property ensures both an active targeting to cells that over-express CD44
and the intracellular delivery of therapeutics. Among the cells, certain cancers, such as breast cancer,
over-express CD44 and, for this reason, HA-based nano-carriers have been especially studied for
cancer therapy and theranostics purposes. The synthesis and application of HA-based nano-carriers
for targeting tumours have been extensively reviewed in a number of works [82,94], and therefore will
be omitted here. However, it should be pointed out, HA is not internalised in all CD44 expressing cell
types: therefore, tumours that highly express CD44 may take up only a little amount of HA [95].
The ability of HA to cross the cell membrane is another important advantage; this attribute
represents an extremely useful strategy to deliver certain drugs intracellularly. Small molecules [87,88],
poly-peptides [65,89,96] and genetic material [86,97] have been efficiently loaded into HA-based
nano-carriers and delivered intracellularly. For example, HA naturally interacts with several proteins
inside the body (hyaladherins) [38] (a number of biological functions of HA are attributed to this
specific binding). Therefore, HA-based nano-carriers could represent a useful system to conjugate
peptides [96] or proteins [71] and deliver them within the body, preserving their activity and increasing
their stability and availability within the tissues. However, the shortcomings of using HA are its rapid
clearance from the blood circulation, due to its recognition by HA receptors of reticuloendothelial
system organs, such as the liver and spleen and subsequent degradation. This is the reason why,
PEGylation is typically used for reducing HA degradation and prolongs its circulation within the
body [98]. However, PEGylation could significantly affect the HA binding affinity to CD44 receptors,
decreasing the nano-carrier cellular uptake in the desired site of action. Therefore, the degree of
functionalisation of HA with PEG and the PEG molecular weight are fundamental parameters that
should be controlled, to increase the nano-carrier circulation in the blood and to decrease their liver
uptake, without affect their internalisation in the targeted site.
Keratinocytes, activated macrophages and fibroblasts are cells that express CD44 and highly take
up extracellular HA, representing another interesting target for HA-based nano-carriers. Recently,
the cellular uptake of HA/chitosan nanoparticles by activated macrophages, for a targeted therapy and
CD44-mediated nucleic acid delivery, has been investigated in depth [97,99]. All these cell types can act
as ‘reservoirs’ for facultative or obligate intracellular pathogens, therefore HA-based nano-carriers may
represent an interesting approach for enhancing the targeting and intracellular uptake of antimicrobials,
opening novel opportunities in this field. In this respect, it should be noted that the sub-cellular
accumulation of antimicrobials in the same site of infection (e.g., endosome, lysosome, cytosol) may
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represent a key point for the effectiveness of the treatments, as different microorganisms can invade
and replicate in different sub-cellular compartments (Figure 2). For example, Mycobacteriae can survive
and replicate within macrophages by resisting lysosomal delivery by residing in early phase endosomal
compartments [100], whilst microorganisms such as Salmonellae [101] and Brucellae [102] survive by
preventing vacuole-lysosome fusion and pathogens such as Shigella spp. [103], Listeria spp. [104]
and Rickettsiae [105] are able to escape from phagosomes and survive in the cytoplasm. To survive
and disseminate intracellularly S. aureus [106,107] and Leishmania [6] appear to resist the fusion of
phagosomes with lysosomes allowing them to multiply within the phagolysosomes of macrophages.
Consequently, when treating an intracellular infection, a suitable antibiotic should be chosen in order to
ensure drug concentration: (I) is above theminimum inhibitory concentration and (II) is delivered to the
site of infection. Depending on their physico-chemical properties, antibiotics accumulate in different
cell compartments at various concentrations [108,109]; typically, weak bases tend to accumulate in
membrane-bound acidic compartments, whereas weak acids are excluded from those sites. Specifically,
aminoglycosides [110] and macrolides [111] predominantly accumulate in lysosomes, quinolones
accumulate in the cytoplasm [111], whereas β-Lactams [112] have been shown to accumulate at low
level within the cells (predominantly in the cytoplasm) likely due to their acidic character.
 ȱ“?
 
Ȯ
Figure 2. Scheme of the intracellular fate of several pathogens and antibiotics.
Therefore, among all the drug delivery systems for antimicrobial activity, the HA-based nano-carriers
may represent a novel paradigm for targeting to cells where pathogens persist, enhancing the intracellular
drug concentration in the specific sub-cellular compartments. Indeed, such nano-carriers can be
customised in order to target lysosomes [113] or to escape the endosome, being released into the
cytoplasm [114].
6. HA-Based Nano-Carriers for Targeting Sub-Cellular Compartments
6.1. Lysosomal HA-Based Nano-Carriers
Even if a number of works have shownHA-based nano-carriers, are internalised by cells especially by
CD44 receptors [115–117], the subsequent intracellular trafficking of these nano-systems is often not clear
or is not investigated. It has been demonstrated self-assembled HA-cholesterol nanohydrogels (HA-CH
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NHs) (HAMw = 2.2 × 10
5, CH degree of functionalisation = 15% (mol/mol, %), mean diameter~180 nm)
quickly accumulate (within 1 h) in acidic endosomal and lysosomal compartments of human keratinocytes
(HaCaT cells), reaching the highest co-localisationwith those vesicles in 4 h [113]. Intracellularly, ApoTome
analysis showed HA-CH NHs located into vesicle-like structures, those with a diameter of approximately
0.3 µm close to the plasma membrane and those in larger vesicles, with diameter up to 1.5 µm close to the
nucleus. A similar outcome was reported by Tammi and colleagues (2001) using free HA in rat epidermal
keratinocytes [20].
Self-assembling oleic acid-ethylendiamine nanoparticles, coated with HA (mean diameter~ 150 nm)
showed co-localisation with lysosomes of colon cancer cells (HCT-116) over 6 h. Moreover, it was found
that this nano-system is taken up by cells through both CD44 and clathrin-dependent endocytosis
routes [117].
The intracellular pathway of polycarbonate: polyethylene: cholesterol (65:5:30) liposomes grafted
with HA has been investigated on human lung carcinoma epithelial cells (A549) and human breast
cancer cell lines (MB-231 and MCF7) [118]. A549 and MB-231 represent CD44 positive cell lines, whilst
MCF7 represents the CD44 negative one. Several HA Mw (from 5.0 × 10
3 to 1.6 × 106) and degree of
grafting density (HA final amount ranging from 0.2 to 1.5 mg) have been employed with the aim to
investigate the impact of these parameters on the liposome uptake (the mean diameter ranged from 120
to 180 nm). Results showed HA-liposomes bind to CD44; this binding increases by increasing either
HA Mw or grafting density (this trend was evident in A549 or MDA-MB-231 cells, but not in MCF7).
Moreover, CD44-mediated uptake of HA-liposomes happened through lipid raft-mediated endocytosis
(that is a cholesterol-dependent route) and it was independent from clathrin-coated vesicles or the
caveolae or macropinocytosis pathways. HA-liposomes were found to be predominantly localised in
acidic endosomal and lysosomal compartments [118].
Taking together these results, it is reasonable to assume that negatively charged and amphiphilic
HA-based nano-carriers (formed by hydrophobic core/domain/particle and HA shell, and showing
a mean diameter smaller than 200 nm) may enter cells especially through CD44 and predominantly
accumulate into lysosomes, by following the endosomal-lysosomal pathway. Consequently, these nano-
systems may be particularly suitable for targeting to pathogens that accumulate and replicate into
these vesicles, such as S. aureus, Leishmania and, possibly, M. tuberculosis.
6.2. Cytosolic HA-Based Nano-Carriers
The nanoparticle uptake through endosomal-lysosomal pathway may show some drawbacks:
(I) in lysosomes, the low pH (~5) and the presence of an array of hydrolytic enzymes may lead
to the destruction of such therapeutic molecules; (II) drugs do not reach the desired site of action,
showing low effectiveness [119,120]. Therefore, recently, a number of strategies have been studied
with the aim to develop nano-carriers that are able to escape the endosome or lysosome and as
such accumulate into the cytoplasm [121]. In 1997, Jean-Paul Behr introduced the concept of ‘proton
sponge’ effect [122] (Figure 3). After endocytosis, the buffering capacity of polycation/polyanion
complexes will tend to both inhibit the action of the lysosomal nucleases (that have an acidic
optimal pH) and alter the osmolarity of the vesicle [122]. The simultaneous occurrence of these
two phenomena will firstly cause the swelling of endosomes/lysosomes and then the breakage of the
vesicle membrane, leading to the release of ‘cargo’ into the cytoplasm. Nano-carriers able to exploit
these properties are typically made of positively charged macromolecules such as polymers with low
pKa amine group (e.g., polyethylenimine, poly-L-lysine, chitosan) or cationic lipids, which have been
especially employed for gene therapy [123]. HA/chitosan nanoparticles represent a typical example of
nano-carrier successfully designed for gene transfection (e.g., DNA, siRNAs) [124]. Their intracellular
trafficking has been studied in phagocytic cells (e.g., macrophages) [114] and human epithelial cell lines
derived from the conjunctiva and the cornea [124], showing the ability of HA/chitosan nanoparticles
to escape lysosomes and target to the cytoplasm. Other examples of HA-based nano-carriers showing
a strong ‘proton sponge’ effect and able to release the cargo in the cytoplasm, are represented by
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core/shell nanoparticles formed of poly(β-amino) ester coated with HA [125] and self-assembled
HA-g-poly(L-histidine) micelles [126]. In order to enhance the endosomal/lysosomal breakage,
a photochemically triggered self-assembling HA-based nanoparticle has been developed [127] by
simultaneously linking a positively charged polymer poly-(diisopropylaminoethyl aspartamide) and
a photosensitizer (chlorin e6) to the carboxyl and hydroxyl groups of acetylated HA, respectively.
For example, these nano-carriers may be employed for targeting to microorganisms that typically
replicate in the cytoplasm, such as Shigella spp. and Listeria spp.
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Figure 3. The ‘proton sponge’ hypothesis: H+ and Cl− enter into the endosome, lead to osmotic
swelling and finally to the endosome breakage.
The endosomal escape can be also achieved by using fusion proteins able to catalyse themembrane
fusion between the particle and endosomes or to generate a pore on the membrane or the lysis of
the membrane in order to empty their ‘cargo’ in the cytoplasm [128]. Also the use of cationic lipids
represents another strategy that could be adopted for destabilizing the endosome membrane [129].
Indeed, after endocytosis, cationic lipids form ion pairs with the anionic ones, leading to the release of
‘cargo’ in the cytoplasm [130]. However, to the best of our knowledge, HA-based nano-carriers which
exploit these properties have not been developed, yet.
7. The Application of HA-Based Nano-Carriers for the Intracellular Delivery of Antimicrobials
With increasing interest in the potential application of HA-based nano-carriers for the intracellular
delivery of antimicrobials, there have been a growing number of investigations looking at their in vitro
and in vivo efficacy. The use of HA-based nano-carriers for antimicrobial purposes could show several
advantages in comparison to those of nano-carriers made of other polymers/materials: (I) a number of
host cells (e.g., keratinocytes and macrophages) express CD44 and highly internalise HA, providing
an active targeting; (II) HA can enter cells through CD44, the receptor also used by pathogens for the
cell invasion; (III) HA-based nano-carriers may be cleaved by HAase that are produced by several
pathogens, such as Staphylococcus spp. and Streptococcus spp. [68], thus facilitating the release of the
drug in situ. The depolymerisation/degradation of HA can also occur in the presence of host enzymes,
free radicals [15], and at low pH values, leading to the intracellular drug release, thus guaranteeing
the efficacy of the targeted therapy also against microorganisms that typically do not produce HAase.
In this scenario, HA-based nano-carriers have been started to be developed and studied for the
intracellular delivery of antimicrobials, both in vitro and in vivo.
A study by using bone-marrow derived macrophages infected with M. tuberculosis or
Mycobacterium avium showed that treatment with an antimicrobial peptide (LLKKK18) entrapped
into self-assembling HA-based NHs provided cellular/sub-cellular targeting and prevented the
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degradation of LLKKK18 by proteases [96]. Specifically: (I) the cytotoxicity of entrapped LLKKK18
was reduced in vitro; (II) the infected macrophages successfully internalised self-assembled HA
NHs; (III) the targeting to mycobacteriae was enhanced using HA NHs even though the exact kind
of vesicles in which the co-localisation occurred was not identified; (IV) experiments carried out
with LLKKK18-loaded NHs showed the new system was more effective against both M. avium and
M. tuberculosis than the free LLKKK18 in vitro and in vivo; (V) un-loaded HA NHs reduced the
infection in mice.
It has also been reported that HA-streptomycin bio-conjugate showed the ability to enhance the
antimicrobial activity of free streptomycin against S. aureus or Listeria monocytogenes in phagocytic cells
(RAWmacrophages) or non-phagocytic cells (VERO) [131]. Authors reported that HA did not improve
the MIC of streptomycin on planktonic pathogens, but did show a high capability to enhance the
antimicrobial activity against the two pathogens within phagocytic and non-phagocytic cells, in vitro
and in vivo. Moreover, HA was able to enhance the streptomycin uptake, which was CD44-mediated
and to reduce the ototoxicity and nephrotoxicity of streptomycin in mice. In previous study by the same
research group, the capability of chitosan-based carriers to improve streptomycin activity intracellularly
was demonstrated [132]. However, the cationic polysaccharide exhibited significant cytotoxicity at
concentration higher than 500 µg/mL.
Investigations have also begun to focus on microorganisms that have not traditionally been
thought as intracellular bacteria as there in increasing evidence suggesting that this mode of growth
may facilitate persistent and chronic infections, and may be a cause of treatment failures. For example,
axenic P. aeruginosa and S. aureus infectedHeLa cells (a model cell line) were incubatedwith levofloxacin
(LVF), a broad spectrum and highly active and cytosolic antibiotic [133], loaded into self-assembled
HA-CH NHs. The reported results showed entrapped LVF was able to eradicate both intracellular
microorganisms after only 2 h of incubation, whilst free LVF was ineffective intracellularly. A similar
study was conducted on human keratinocytes (HaCaT cells) infected with S. aureus [113]; infected
cells were incubated with LVF or gentamicin (GM)-loaded HA-CH NHs or their controls (free LVF,
GM, NHs). These two antibiotics were selected as they have different intracellular pathways: LVF
is a cytosolic drug, whilst GM is a lysosomal one. Results showed that NHs highly enhanced
the antimicrobial activity of LVF against the intracellular S. aureus, but they did not improve the
antibacterial activity of GM, which showed a significant effect without the employment of NHs. As it
has been demonstrated that NHs co-localise with lysosomes of HaCaT cells and it is known that
free LVF predominantly accumulates in the cytoplasm, these results suggested NHs may be able
to change the intracellular fate of LVF from cytoplasm to lysosome, thereby targeting intracellular
S. aureus, illustrating the importance of a targeted antibiotic treatment, and the the opportunity to
enhance the intracellular activity of such antibiotics by using HA-based nano-carriers. It should be
noted that, in both works, extracellular pathogens were previously eliminated, and the LVF-loaded
NHs were tested only against the intracellular microorganisms. Though it is still not clear where the
sub-cellular sites in which the loaded antibiotic was acting, the experiment was designed to remove any
extracellular pathogen, so only intracellular microorganisms were counted after treatment. Moreover,
as the free NHs was not effective against both intracellular and extracellular pathogens, it can be stated
the antibacterial activity was only due to the intracellular LVF [113,133].
Recently, HA-amikacin was synthesised by ‘click’ reaction between HA-propargyl amide and
amikacin-azide [134]. The obtained bio-conjugate was tested against planktonic P. aeruginosa, S. aureus
and L. monocytogenes; HA did not improve the MIC of amikacin on planktonic pathogens, but did
show a high capability to enhance the antimicrobial activity against the three pathogens within RAW
264.7 macrophages. The bio-conjugate was then tested in vivo, on mice infected intraperitoneally
with L. monocytogenes, which received subcutaneous injection of HA-amikacin or its controls. Like the
in vitro results suggested, the bio-conjugate showed an improvement of the antimicrobial activity
of amikacin, evidencing the HA capability to enhance the efficacy of the antimicrobial against such
intracellular pathogen. To the best of our knowledge, these are the only examples which describe the
Molecules 2018, 23, 939 12 of 18
development and use of HA-based nano-carriers for targeting to intracellular pathogens. None of
these works has shown a significant increase in toxicity of the loaded antimicrobials, both in vitro
and in vivo. In contrast, a significant toxicity has been noted for chitosan-based nanoparticles [132],
However, further studies are necessary to increase the understanding of the possible side effects that
loaded antibiotics may cause (e.g., long-term side effects), the way in which the loaded antibiotics
are acting against both intracellular and extracellular pathogens and the intracellular pathways
that are involved in the uptake of these nano-formulations. Further investigations promise to be
very productive.
8. Conclusions and Perspectives
The relationship between HA, CD44 and the invasion and survival of a number of pathogens
within the cells is becoming increasingly evident. Several microorganisms utilise CD44 and/or HA
to enter and replicate within the cellular micro-environment. Furthermore, a number of host cells
highly express CD44 and internalise HA, ensuring an intracellular uptake of antimicrobials loaded
into HA-based nano-carriers. This scenario makes HA a possible candidate for the development of
‘Trojan Horse’ systems to target intracellular microorganisms, thus overcoming the ineffectiveness
of many antibiotics intracellularly. Previous works showed the ability of HA-based nano-carriers
to enhance the intracellular activity of certain antimicrobials; however, little has been carried out
in biology, microbiology and drug delivery fields, therefore further studies are necessary. HA is
already extensively used for topical administration in cosmetics or ophthalmology. The incorporation
of antimicrobials within HA-based nanogels may represent an interesting approach for enhancing
the intracellular delivery of some drugs, thus targeting to pathogens that are a common cause of
chronic topical infections (e.g., S. aureus) [113]. Moreover, the local HA administration could reduce
the drawbacks due to the in vivo uptake and catabolism of HA into cells that express LYVE-1 or
HARE (e.g., liver and kidney). This aspect reduces the efficacy of the targeted therapy, representing
an important disadvantage for HA-based injectable formulations. Several strategies have however
been found for overcoming these drawbacks; for example, stealth HA nanoparticles have been shown
to reduce the uptake by liver and kidney, improving the targeting to the desired site of action [98].
Toxicity is another aspect that must be taken into account: HA carriers should be able to enhance the
intracellular uptake of antimicrobials and possibly, change their intracellular trafficking. So far, none of
the authors reported a significant increase in toxicity of the loaded antibiotics in their experiments,
both in vitro and in vivo but further work is necessary before clinical applications are fully realised.
Furthermore, in the alveolar tracts, released fragments of HA play a pivotal role in the host defences
stimulating the innate immune responses, by activating TLR2 and TLR4 receptors, thus inducing
lung inflammation. There is a great deal of published and ongoing work into the role of HA during
the inflammation processes even though a number of mechanisms are not yet clarified and with the
indication that some pathogens may take advantage of these pathways for invading and surviving
within host cells; this information is far from being clearly elucidated and our understanding in this
area should be improved.
Antibiotic resistance is one of the major public health threats, and the novel approach based on
HA nano-carries may represent an interesting strategy for overcoming some antibiotic failures in the
treatment of intracellular infections.
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